PE20081317A1 - Formas de cristal de la epotilona b - Google Patents
Formas de cristal de la epotilona bInfo
- Publication number
- PE20081317A1 PE20081317A1 PE2007001090A PE2007001090A PE20081317A1 PE 20081317 A1 PE20081317 A1 PE 20081317A1 PE 2007001090 A PE2007001090 A PE 2007001090A PE 2007001090 A PE2007001090 A PE 2007001090A PE 20081317 A1 PE20081317 A1 PE 20081317A1
- Authority
- PE
- Peru
- Prior art keywords
- epotilone
- crystal forms
- intensity
- refers
- values
- Prior art date
Links
- 239000013078 crystal Substances 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 238000010586 diagram Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 abstract 1
- 229940011051 isopropyl acetate Drugs 0.000 abstract 1
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
SE REFIERE A FORMAS CRISTALINAS DE LA EPOTILONA B, EN ESPECIAL DE LA FORMA DESCRITA COMO MODIFICACION C; CARACTERIZADA POR PRESENTAR UN DIAGRAMA DE DIFRACCION DE RAYOS-X EXPRESADOS EN VALORES DE 2?; DONDE LOS VALORES DE LOS PICOS CUANDO LA INTENSIDAD ES FUERTE SON: 17,5 Y 18,3; CUANDO LA INTENSIDAD ES MEDIA SON: 6,5; 11,8; 13,1; 17,5; 18,3; 19,6; 21,6; DONDE DICHA FORMA ES CRISTALIZADA A PARTIR DE ACETATO DE ISOPROPILO. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA Y UN PROCEDIMIENTO DE PREPARACION; SIENDO UTILES EN TRATAMIENTO DE ENFERMEDADES PROLIFERATIVAS TALES COMO TUMORES
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06119043 | 2006-08-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20081317A1 true PE20081317A1 (es) | 2008-10-28 |
Family
ID=37685905
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2007001090A PE20081317A1 (es) | 2006-08-16 | 2007-08-14 | Formas de cristal de la epotilona b |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US8178566B2 (es) |
| EP (1) | EP2064216A2 (es) |
| JP (1) | JP2010500387A (es) |
| KR (1) | KR20090038902A (es) |
| CN (1) | CN101506217B (es) |
| AR (1) | AR062375A1 (es) |
| AU (1) | AU2007286454A1 (es) |
| BR (1) | BRPI0715963A2 (es) |
| CA (1) | CA2658475A1 (es) |
| CL (1) | CL2007002362A1 (es) |
| IL (1) | IL196558A0 (es) |
| MA (1) | MA30656B1 (es) |
| MX (1) | MX2009001635A (es) |
| MY (1) | MY148355A (es) |
| NO (1) | NO20091081L (es) |
| NZ (1) | NZ574194A (es) |
| PE (1) | PE20081317A1 (es) |
| RU (1) | RU2009109352A (es) |
| TN (1) | TN2009000044A1 (es) |
| TW (1) | TW200815455A (es) |
| WO (1) | WO2008019820A2 (es) |
| ZA (1) | ZA200900227B (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110300150A1 (en) | 2010-05-18 | 2011-12-08 | Scott Eliasof | Compositions and methods for treatment of autoimmune and other disease |
| CN103910742B (zh) * | 2013-01-07 | 2016-07-13 | 浙江海正药业股份有限公司 | 一种制备埃博霉素b无定形粉末的方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2324378T3 (es) | 1998-02-05 | 2009-08-05 | Novartis Ag | Composicion farmaceutica que contiene epotilona. |
| US6194181B1 (en) * | 1998-02-19 | 2001-02-27 | Novartis Ag | Fermentative preparation process for and crystal forms of cytostatics |
| UA75365C2 (en) * | 2000-08-16 | 2006-04-17 | Bristol Myers Squibb Co | Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon |
| GB0029895D0 (en) | 2000-12-07 | 2001-01-24 | Novartis Ag | Organic compounds |
| HRP20050278A2 (en) * | 2002-09-23 | 2005-10-31 | Bristol-Myers Squibb Company | Methods for the preparation, isolation and purification of epothilone b, and x-ray crystal structures of epothilone b |
-
2007
- 2007-08-14 WO PCT/EP2007/007173 patent/WO2008019820A2/en not_active Ceased
- 2007-08-14 JP JP2009524113A patent/JP2010500387A/ja active Pending
- 2007-08-14 NZ NZ574194A patent/NZ574194A/en not_active IP Right Cessation
- 2007-08-14 PE PE2007001090A patent/PE20081317A1/es not_active Application Discontinuation
- 2007-08-14 RU RU2009109352/04A patent/RU2009109352A/ru not_active Application Discontinuation
- 2007-08-14 AR ARP070103603A patent/AR062375A1/es not_active Application Discontinuation
- 2007-08-14 CL CL200702362A patent/CL2007002362A1/es unknown
- 2007-08-14 US US12/376,973 patent/US8178566B2/en not_active Expired - Fee Related
- 2007-08-14 BR BRPI0715963-3A patent/BRPI0715963A2/pt not_active IP Right Cessation
- 2007-08-14 AU AU2007286454A patent/AU2007286454A1/en not_active Abandoned
- 2007-08-14 MX MX2009001635A patent/MX2009001635A/es not_active Application Discontinuation
- 2007-08-14 MY MYPI20090415A patent/MY148355A/en unknown
- 2007-08-14 KR KR1020097002958A patent/KR20090038902A/ko not_active Ceased
- 2007-08-14 CA CA002658475A patent/CA2658475A1/en not_active Abandoned
- 2007-08-14 CN CN2007800304132A patent/CN101506217B/zh not_active Expired - Fee Related
- 2007-08-14 EP EP07801648A patent/EP2064216A2/en not_active Withdrawn
- 2007-08-15 TW TW096130206A patent/TW200815455A/zh unknown
-
2009
- 2009-01-12 ZA ZA2009/00227A patent/ZA200900227B/en unknown
- 2009-01-15 IL IL196558A patent/IL196558A0/en unknown
- 2009-02-13 TN TN2009000044A patent/TN2009000044A1/fr unknown
- 2009-02-20 MA MA31654A patent/MA30656B1/fr unknown
- 2009-03-11 NO NO20091081A patent/NO20091081L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CN101506217A (zh) | 2009-08-12 |
| MY148355A (en) | 2013-03-29 |
| IL196558A0 (en) | 2009-11-18 |
| US8178566B2 (en) | 2012-05-15 |
| MX2009001635A (es) | 2009-02-23 |
| RU2009109352A (ru) | 2010-09-27 |
| BRPI0715963A2 (pt) | 2013-08-06 |
| AU2007286454A1 (en) | 2008-02-21 |
| AR062375A1 (es) | 2008-11-05 |
| MA30656B1 (fr) | 2009-08-03 |
| WO2008019820A3 (en) | 2008-04-17 |
| US20100160393A1 (en) | 2010-06-24 |
| TW200815455A (en) | 2008-04-01 |
| KR20090038902A (ko) | 2009-04-21 |
| TN2009000044A1 (en) | 2010-08-19 |
| EP2064216A2 (en) | 2009-06-03 |
| CL2007002362A1 (es) | 2008-08-08 |
| CN101506217B (zh) | 2012-09-05 |
| JP2010500387A (ja) | 2010-01-07 |
| WO2008019820A2 (en) | 2008-02-21 |
| ZA200900227B (en) | 2009-12-30 |
| NO20091081L (no) | 2009-03-16 |
| NZ574194A (en) | 2011-12-22 |
| CA2658475A1 (en) | 2008-02-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR128483A2 (es) | Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino}acético, sus composiciones y usos | |
| AU2016202535B2 (en) | Fused heterocyclic compounds as sodium channel modulators | |
| PH12013502549B1 (en) | Fused benzoxazepinones as ion channel modulators | |
| AR112816A2 (es) | Compuestos que inhiben el enlace de la proteína smac al inhibidor de proteínas de apoptosis (iap) | |
| PE20120989A1 (es) | Sales de disacarina, acido difumarico, acido d-1-hidroxi-2-naftoico y monobenzoico del 2-(4-((2-amino-4-metil-6-(pentilamino) pirimidin-5-il) metil) fenil) acetato de 4-(dimetilamino) butilo | |
| EA026385B9 (ru) | Конденсированные гетероциклические соединения в качестве модуляторов ионных каналов | |
| EA201290988A1 (ru) | Стереоселективный синтез фосфорсодержащих активных соединений | |
| PE20142353A1 (es) | Ansolvatos de sal de noribogaina | |
| EA201690899A1 (ru) | Оксазепины в качестве модуляторов ионных каналов | |
| EA201001555A1 (ru) | Антиоксидативные модуляторы воспаления: производные олеанолевой кислоты с аминовыми и другими модификациями на с-17 | |
| CN103717571B8 (zh) | 9‑氨基甲基取代的四环素类化合物 | |
| CA2900335C (en) | Synthetic analogs of epipolythiodioxopiperazines and uses thereof | |
| EA201390993A1 (ru) | Антитела к cd38 | |
| CN102036649A8 (zh) | 精氨酸盐及其治疗口腔疾病的用途 | |
| EA201491623A1 (ru) | Замещенные пирролидин-2-карбоксамиды | |
| WO2007101864A3 (en) | Compounds that modulate ppar activity, their preparation and use | |
| CL2013002341A1 (es) | Compuestos derivados de 6-ciclobutil-1,5-dihidro-pirazolo [3,4 d]pirimidin-4-ona, inhibidores de pde9a; composicion farmaceutica; y su uso para el tratamiento de una enfermedad o afección relacionado con deterioro cognitivo, enfermedad de alzheimer, demencia vascular, entre otros | |
| WO2013028818A8 (en) | Pyrimido- pyridazinone compounds and use thereof | |
| JP2013528182A5 (es) | ||
| WO2010139979A3 (en) | Processes for preparing crystalline forms of dasatinib | |
| AR080275A1 (es) | Formas solidas de un derivado de n-( fenilmetil) propanamida y procedimientos de preparacion | |
| CL2013000756A1 (es) | Forma cristalaina del citrato diacido de (4s)-4-(5-fenil-1,3,4-tiadiazol-2-iloxi)-1-azatriciclo[3.3.1.13,7]decano; proceso de preparacion; composicion farmaceutica; y su uso para tratar o prevenir un trastorno de la memoria, un trastorno cognitivo, neurodegeneracion, entre otros. | |
| PE20081556A1 (es) | Formas cristalinas de glyt1 | |
| AR084832A1 (es) | Derivado cristalino de oxazina | |
| AR057099A1 (es) | Una forma cristalina, un proceso de preparacion y composicion farmaceutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |